文献速递淋巴瘤

阿替利珠单抗、奥妥珠单抗和维奈克拉治疗复发/难治性B细胞非霍奇金淋巴瘤:LYSA协作组II期试验最终分析

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.
PubMed 文献 · Br J Haematol · 2025-04-26

这项由LYSA推动的多中心II期试验(NCT03276468)评估阿替利珠单抗、奥妥珠单抗和维奈克拉联合方案治疗既往接受过至少一种含抗CD20免疫化疗方案的复发/难治性B细胞非霍奇金淋巴瘤患者,纳入滤泡性淋巴瘤(FL,n=58)、弥漫性大B细胞淋巴瘤(DLBCL,n=58)和边缘区淋巴瘤(MZL,n=20)。FL和DLBCL的主要终点未达到:诱导结束时FL组客观缓解率为53.6%(预期至少70%),DLBCL组为23.6%(预期至少48%);MZL组诱导结束时客观缓解率为66.7%。中位无进展生存期FL组为11.0个月,DLBCL组为2.7个月。最常见不良事件为血细胞减少,7.4%的自身免疫不良事件可归因于联合方案。

要点

  • FL和DLBCL的主要终点未达到:诱导结束时ORR分别为53.6%和23.6%,低于预期的70%和48%。
  • 中位无进展生存期FL组为11.0个月,DLBCL组为2.7个月;MZL组诱导结束时ORR为66.7%。
  • 最常见不良事件为血细胞减少,7.4%的自身免疫不良事件可归因于联合方案。

核心结论

  • 在该II期试验中,阿替利珠单抗、奥妥珠单抗和维奈克拉联合方案作为诱导和维持治疗显示出中等疗效和可控的毒性特征。
  • FL和DLBCL的主要终点未达到:诱导结束时ORR分别为53.6%和23.6%,低于预期的70%和48%。

研究设计与样本

  • LYSA推动的多中心II期试验(NCT03276468),评估阿替利珠单抗、奥妥珠单抗和维奈克拉联合方案治疗既往接受过至少一种含抗CD20免疫化疗方案的复发/难治性B细胞非霍奇金淋巴瘤患者。
  • 纳入滤泡性淋巴瘤(FL,n=58)、弥漫性大B细胞淋巴瘤(DLBCL,n=58)和边缘区淋巴瘤(MZL,n=20)。

主要发现

  • FL组(队列1)诱导结束时ORR为53.6%,DLBCL组(队列2)为23.6%,MZL组(队列3)为66.7%。
  • 中位无进展生存期FL组为11.0个月,DLBCL组为2.7个月。
  • 最常见不良事件为血细胞减少,7.4%的自身免疫不良事件可归因于联合方案。

关键数值与推荐

  • FL组主要终点未达到:诱导结束时ORR为53.6%,预期至少70%。
  • DLBCL组主要终点未达到:诱导结束时ORR为23.6%,预期至少48%。
  • MZL组诱导结束时ORR为66.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Developing new therapeutic regimens for relapsed/refractory (R/R) B non-Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti-CD20-containing immunochemotherapy regimen. We report here the final analysis of the phase II LYSA-promoted multicentre trial (NCT03276468) of this combination in follicular lymphoma (FL, n = 58), diffuse large B-cell lymphoma (DLBCL, n = 58) and marginal zone lymphoma (MZL, n = 20). The primary end-point for FL and DLBCL was not met: ATE, OBI, and VEN resulted in an overall response rate (ORR) at the end of induction (EOI) of 53.6% for FL (cohort 1) and 23.6% for DLBCL (cohort 2) when a minimum of 70% and 48% was expected respectively. The median progression-free survival was 11.0 and 2.7 months in cohorts 1 and 2 respectively. In cohort 3 (MZL), the ORR at the EOI was evaluated at 66.7%. The most frequent adverse events (AEs) were cytopenias. We also observed 7.4% of autoimmune AE imputable to the combination. In this phase II study, ATE, OBI and VEN demonstrated moderate efficacy and a manageable toxicity profile when used as induction and maintenance therapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Herbaux C, Bachy E, Bouabdallah R, et al. Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group. Br J Haematol. 2025. PMID: 40285420. doi:10.1111/bjh.20109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。